Sign up to save your podcasts
Or
Share GoodRx: Is it Today’s hims & hers? 8-18-25
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
GoodRx: Is it Today’s hims & hers? 8-18-25
In this episode, Scott Becker examines GoodRx’s 30% surge after entering the weight loss drug market, the rapid growth of hims and hers, and Novo Nordisk’s move to cut prices on Ozempic as competition in the GLP-1 space intensifies.
View all episodes
By Becker Private Equity & BusinessIn this episode, Scott Becker examines GoodRx’s 30% surge after entering the weight loss drug market, the rapid growth of hims and hers, and Novo Nordisk’s move to cut prices on Ozempic as competition in the GLP-1 space intensifies.